Drug
Lepetegravir clinical trials
Also written GS-1720.
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Lenacapavir pacfosacil (2) · Bavtavirine (1) · GS-6212 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Integrase Inhibitors source
Studies
Open first, then newest update. How each study uses lepetegravir is read from its arms, and is right about nine times in ten.
Testing it · 3
- Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedActive, not recruitingPhase 2/3Gilead SciencesNCT06544733Written as Lepetegravir
- Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedTerminatedPhase 2/3Gilead SciencesNCT06613685Written as lepetegravir
- Study of Novel Antiretrovirals in Participants With HIV-1CompletedPhase 1Gilead SciencesNCT05585307Written as GS-1720
Codes
What other systems call lepetegravir · ClinicalTrials.gg INT018099
- UNII (FDA) U7N3Q737CALEPETEGRAVIRConfirmed FDA, Wikidata
- Wikidata Q140529179lepetegravirConfirmed FDA, Wikidata
- NCI Thesaurus C223288LepetegravirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U7N3Q737CA | LEPETEGRAVIR | Confirmed FDA, Wikidata |
| Wikidata | Q140529179 | lepetegravir | Confirmed FDA, Wikidata |
| NCI Thesaurus | C223288 | Lepetegravir | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.